PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Elliott Boulding sold 15,521 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $53.30, for a total value of $827,269.30. Following the transaction, the vice president now directly owns 103,901 shares of the company’s stock, valued at $5,537,923.30. The trade was a 13.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Mark Elliott Boulding also recently made the following trade(s):
- On Wednesday, February 19th, Mark Elliott Boulding sold 1,333 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.10, for a total value of $66,783.30.
- On Tuesday, January 7th, Mark Elliott Boulding sold 1,543 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $69,959.62.
PTC Therapeutics Stock Performance
Shares of PTCT stock opened at $54.50 on Friday. PTC Therapeutics, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $55.65. The stock has a 50 day moving average price of $48.60 and a two-hundred day moving average price of $43.57. The company has a market capitalization of $4.30 billion, a P/E ratio of -9.18 and a beta of 0.66.
Institutional Trading of PTC Therapeutics
Wall Street Analyst Weigh In
Several research analysts have recently commented on PTCT shares. Robert W. Baird boosted their price objective on PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Royal Bank of Canada boosted their price objective on PTC Therapeutics from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Wells Fargo & Company boosted their target price on PTC Therapeutics from $56.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 26th. Bank of America upgraded PTC Therapeutics from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $41.00 to $55.00 in a research report on Tuesday, March 11th. Finally, StockNews.com downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $64.00.
Read Our Latest Research Report on PTC Therapeutics
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Stories
- Five stocks we like better than PTC Therapeutics
- Basic Materials Stocks Investing
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Conference Calls and Individual Investors
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- ETF Screener: Uses and Step-by-Step Guide
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.